Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106


Non-secretory myeloma: a clinician's guide.

Lonial S, Kaufman JL.

Oncology (Williston Park). 2013 Sep;27(9):924-8, 930. Review.


Investigative tools for diagnosis and management.

Munshi NC.

Hematology Am Soc Hematol Educ Program. 2008:298-305. doi: 10.1182/asheducation-2008.1.298.


New tools for diagnosis and monitoring of multiple myeloma.

San-Miguel JF, Paiva B, Gutiérrez NC.

Am Soc Clin Oncol Educ Book. 2013. doi: 10.1200/EdBook_AM.2013.33.e313. Review.


Myeloma genetics and genomics: practice implications and future directions.

Faiman B.

Clin Lymphoma Myeloma Leuk. 2014 Dec;14(6):436-40. doi: 10.1016/j.clml.2014.07.008. Epub 2014 Jul 14. Review.


The evolving use of serum free light chain assays in haematology.

Pratt G.

Br J Haematol. 2008 May;141(4):413-22. doi: 10.1111/j.1365-2141.2008.07079.x. Epub 2008 Mar 3. Review.


Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study.

Rawstron AC, Child JA, de Tute RM, Davies FE, Gregory WM, Bell SE, Szubert AJ, Navarro-Coy N, Drayson MT, Feyler S, Ross FM, Cook G, Jackson GH, Morgan GJ, Owen RG.

J Clin Oncol. 2013 Jul 10;31(20):2540-7. doi: 10.1200/JCO.2012.46.2119. Epub 2013 Jun 3. Erratum in: J Clin Oncol. 2013 Dec 1;31(34):4383.


Multiple myeloma.

White TB, Caldwell D, Hall-Rollins J.

Radiol Technol. 2005 May-Jun;76(5):379-88; quiz 389-91. Review.


Whole-body MRI and PET/CT in multiple myeloma patients during staging and after treatment: personal experience in a longitudinal study.

Cascini GL, Falcone C, Console D, Restuccia A, Rossi M, Parlati A, Tamburrini O.

Radiol Med. 2013 Sep;118(6):930-48. doi: 10.1007/s11547-013-0946-7. Epub 2013 Jun 26.


International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders.

Dispenzieri A, Kyle R, Merlini G, Miguel JS, Ludwig H, Hajek R, Palumbo A, Jagannath S, Blade J, Lonial S, Dimopoulos M, Comenzo R, Einsele H, Barlogie B, Anderson K, Gertz M, Harousseau JL, Attal M, Tosi P, Sonneveld P, Boccadoro M, Morgan G, Richardson P, Sezer O, Mateos MV, Cavo M, Joshua D, Turesson I, Chen W, Shimizu K, Powles R, Rajkumar SV, Durie BG; International Myeloma Working Group.

Leukemia. 2009 Feb;23(2):215-24. doi: 10.1038/leu.2008.307. Epub 2008 Nov 20. Review.


A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma.

Zamagni E, Nanni C, Patriarca F, Englaro E, Castellucci P, Geatti O, Tosi P, Tacchetti P, Cangini D, Perrone G, Ceccolini M, Brioli A, Buttignol S, Fanin R, Salizzoni E, Baccarani M, Fanti S, Cavo M.

Haematologica. 2007 Jan;92(1):50-5.


Challenges and opportunities of novel imaging techniques in monoclonal plasma cell disorders: imaging "early myeloma".

Hillengass J, Landgren O.

Leuk Lymphoma. 2013 Jul;54(7):1355-63. doi: 10.3109/10428194.2012.740559. Epub 2013 Jan 28. Review.


Serum free light chains in myeloma patients with an intact M protein by immunofixation: potential roles for response assessment and prognosis during induction therapy with novel agents.

Mori S, Crawford BS, Roddy JV, Phillips G, Elder P, Hofmeister CC, Efebera Y, Benson DM Jr.

Hematol Oncol. 2012 Sep;30(3):156-62. doi: 10.1002/hon.1019. Epub 2011 Oct 26.


[Updated criteria for diagnosis and risk stratification in patients with multiple myeloma].

Djurdjević P, Andjelković N, Bila J.

Srp Arh Celok Lek. 2011 Dec;139 Suppl 2:95-102. Serbian.


Inability of a monoclonal anti-light chain antibody to detect clonal plasma cells in a patient with multiple myeloma by multicolor flow cytometry.

van Velzen JF, van den Blink D, Bloem AC.

Cytometry B Clin Cytom. 2013 Jan-Feb;84(1):30-2. doi: 10.1002/cyto.b.21044. Epub 2012 Sep 27.


Immunophenotypic heterogeneity of normal plasma cells: comparison with minimal residual plasma cell myeloma.

Liu D, Lin P, Hu Y, Zhou Y, Tang G, Powers L, Medeiros LJ, Jorgensen JL, Wang SA.

J Clin Pathol. 2012 Sep;65(9):823-9. doi: 10.1136/jclinpath-2012-200881. Epub 2012 Jun 8.


Evaluation of minimal residual disease in multiple myeloma patients by fluorescent-polymerase chain reaction: the prognostic impact of achieving molecular response.

Martínez-Sánchez P, Montejano L, Sarasquete ME, García-Sanz R, Fernández-Redondo E, Ayala R, Montalbán MA, Martínez R, García Laraña J, Alegre A, Hernández B, Lahuerta JJ, Martínez-López J.

Br J Haematol. 2008 Sep;142(5):766-74. doi: 10.1111/j.1365-2141.2008.07263.x. Epub 2008 Jul 8.


Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3.

Dimopoulos M, Kyle R, Fermand JP, Rajkumar SV, San Miguel J, Chanan-Khan A, Ludwig H, Joshua D, Mehta J, Gertz M, Avet-Loiseau H, Beksaç M, Anderson KC, Moreau P, Singhal S, Goldschmidt H, Boccadoro M, Kumar S, Giralt S, Munshi NC, Jagannath S; International Myeloma Workshop Consensus Panel 3.

Blood. 2011 May 5;117(18):4701-5. doi: 10.1182/blood-2010-10-299529. Epub 2011 Feb 3.


Early prediction of treatment response to high-dose salvage chemotherapy in patients with relapsed germ cell cancer using [(18)F]FDG PET.

Bokemeyer C, Kollmannsberger C, Oechsle K, Dohmen BM, Pfannenberg A, Claussen CD, Bares R, Kanz L.

Br J Cancer. 2002 Feb 12;86(4):506-11.

Items per page

Supplemental Content

Support Center